CTVA vs NUE

Corteva (CTVA) trades at a premium valuation with mixed profitability trends and strong recent earnings surprises, though near-term earnings growth remains challenged. The stock has underperformed over the past six months (-3.3%) despite solid 1-year and 5-year returns (+16.1%, +85.9%), reflecting macro pressures in agricultural inputs. While revenue growth of 12.6% outpaces the sector average of 6.16%, negative operating margins (-10.31%) and volatile quarterly EPS performance raise concerns about execution and cost structure. Analysts are constructive with a $77.71 target implying 17.7% upside, but recent insider selling adds caution, offsetting an otherwise healthy balance sheet and sustainable dividend policy.

NUE presents a dichotomy between exceptional growth and deteriorating momentum, anchored by a stable Piotroski F-Score of 4/9. While the company exhibits explosive YoY earnings growth (382.10%) and a rock-solid balance sheet (Debt/Equity 0.32), the stock is currently trading at its 52-week high ($225.29 vs $227.48) despite a severely bearish technical trend (10/100). The valuation is stretched, as evidenced by a high PEG ratio of 5.21 and a current price significantly above the Graham Number of $144.15, suggesting the market has already priced in most of the growth.